Comparative Pharmacology
Head-to-head clinical analysis: ACTAHIST versus BENADRYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTAHIST versus BENADRYL.
ACTAHIST vs BENADRYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; binds to histamine H1 receptors, blocking the effects of histamine; also exhibits anticholinergic and mild sedative properties.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
1.34 mg (one capsule) orally twice daily.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
None Documented
None Documented
6.9 ± 1.7 hours in adults; prolonged to 12-18 hours in elderly or patients with hepatic impairment, requiring dosing interval adjustment.
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Primarily renal (approximately 85% as unchanged drug and metabolites) and fecal (15%) via biliary elimination.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Category C
Category C
Antihistamine
Antihistamine